Skip to content

Radiomics Prediction Model of Response to Immunotherapy Plus Targeted Therapy in Advanced Renal Cell Carcinoma Based on Multiparametric MRI and Correlational Analysis with Pathological Molecular Phenotype

Radiomics Prediction Model of Response to Immunotherapy Plus Targeted Therapy in Advanced Renal Cell Carcinoma Based on Multiparametric MRI and Correlational Analysis with Pathological Molecular Phenotype

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400087093
Enrollment
Unknown
Registered
2024-07-19
Start date
2024-08-01
Completion date
Unknown
Last updated
2024-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced clear cell renal cell carcinoma

Interventions

Gold Standard:Response Evaluation Criteria in Solid Tumors,RECIST 1.1

Sponsors

Department of Radiology, First Medical Center of Chinese PLA General Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. Age greater than 18; 2. Historical imaging data suggests diagnosis of advanced clear cell renal cell carcinoma (ccRCC). 3. Complete renal MRI images: including non-contrast-enhanced images, contrast-enhanced images, and functional imaging sequences. 4. Complete clinical, laboratory, and pathological information, including age, gender, body mass index (BMI), smoking history, diabetes history, complete blood count, World Health Organization/International Society of Urological Pathology (WHO/ISUP) nuclear grading, sarcomatous differentiation, immunohistochemistry results, etc.

Exclusion criteria

Exclusion criteria: 1. Prior history of targeted therapy, immunotherapy, or radiotherapy and chemotherapy. 2. Percutaneous renal biopsy had been performed prior to MRI examination. 3. Insufficient MRI scan quality, including obvious imaging artifacts and incomplete MRI coverage 4. The primary lesion cannot be evaluated using the Response Evaluation Criteria in Solid Tumors, RECIST 1.1.

Design outcomes

Primary

MeasureTime frame
Area under the receiver operating characteristic curve;

Secondary

MeasureTime frame
Sensitivity;Specificity;Accuracy;

Countries

China

Contacts

Public ContactHaiyi Wang

Department of Radiology, First Medical Center of Chinese PLA General Hospital

wanghaiyi301@outlook.com+86 186 1203 2510

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026